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Transforming growth factor-beta (TGF-beta) is known to 
stimulate dermal wound healing events (fibroplasia and fi-
brosis). In this study, the effect of TGF-beta on epidermal 
wound healing (re-epithelialization) was examined. Epider-
mal cell outgrowth from partial-thickness porcine skin ex-
plants was used as an in vitro model for epithelialization. All 
cultures were grown in medium with 1 % fetal bovine serum, 
which was sufficient for explant viability but low enough to 
permit measurement of modulation by added factors. Be-
cause TGF-beta is known to act in concert with other growth 
factors, it was evaluated alone and in the presence of epider-
mal growth factor (EGF) and platelet-derived growth factor 
(PDGF). The results indicate that TGF-beta produced earlier 
initiation of outgrowth, by 1 - 2 d compared with control 
cultures, and increased the rate of outgrowth during the mi-
gratory phase of culture (Days 1-3). Compared to controls, 
T ransforming growth factor-beta (TGF-beta) was first identified and is still defined based on its ability to reversibly induce the transformed phenotype (an-chorage-independent growth) in certain non trans-. formed (anchorage-dependent) cells [2]. Although 
TGF-beta was first found in the conditioned medium of virally 
transformed neoplastic murine cells [3], TGF-beta and its receptor 
have been found in a wide range of normal and transformed mam-
malian cells and cell lines [4] . Roberts and Sporn suggest that the 
TGF-beta receptor may be essentia l to ce ll viability and TGF-beta is 
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EGF alone produced a greater percentage of growing ex~ 
plants and an increased rate of outgrowth during the mitotic 
phase (Days 4 - 7). TGF-beta (1 or 10 ng/ml) and EGF 
(5 ng/ml) had an additive rather than a synergistic effect on 
outgrowth. PDGF-treated explants did not show enhanced 
growth when PDGF (2.5 units/ml) was added alone or to-
gether with TGF-beta and EGF. The ability ofTGF-beta to 
produce earlier initiation of outgrowth was not due to an 
effect on mitosis, because TGF-beta did not increase the in-
corporation of [3H]thymidine into keratinocytes in the 
growin g epidermal sheets. Rather, it is likely that TGF-beta 
facilitated keratinocyte migration, possibly by unmasking a 
receptor on the epidermal cell surface. These results suggest 
that TGF-beta may playa role in early epidermal wound 
healing. ] Invest Dermato! 91 :440 - 445, 1988 
thought to playa different and more fundamental role in the biol-
ogy of a cell than that of mitogenic pep tides such as EGF, PDGF, or 
insulin-like growth factors [4] . TGF-beta is a bifunctional regulator 
of cel l growth [5 - 8]; although initially identified as a growth stim-
ulator it has si nce been found to inhibit mitosis in certain cells in 
culture. In some cases its mode of action (stimulatory or inhibitory) 
is determined by the concentration of TGF-beta, the presence or 
absence of other cytokines, and other culture conditions [4]. More 
recen tl y, TGF-beta has been shown to have a variety of other activi-
ties unrelated to cell proliferation; for example, in fibroblasts it 
enhances the production of extracellular matrix molecules collagen 
[9 - 11]. fibronectin [11], and glycosaminoglycan [12], and helps 
stabilize matrix proteins by stimulating protease inhibitors and de-
creasi ng the extracellular levels of certain proteases produced by 
fibroblasts [13] . 
TGF-beta injected into subdermal wound chambers produces in-
creases in DNA, total protein, and collagen biosynthesis [14] . Sub-
cutaneous injections of TGF-beta into the necks of newborn mice 
produce fibrotic nodules with an increased number of fibroblasts 
and increased collagen synthesis [4,9]' 
Assoian et al discovered that human blood platelets are a major 
storage site for TGF-beta [15] and that TGF-beta is released during 
platelet degranulation [16]. Recently Roberts et al [9] reported that 
TGF-beta is secreted by activated T lymphocytes. Therefore, TGF-
beta may be an important factor for tissue repair that is carried to the 
site of injury and released by activated platelets and lymphocytes. In 
the studies reported here, the potential role ofTGF-beta in epider-
Illal healing was investigated by determining the effects of TGF-
beta on epidermal cell outgrowth from explants. 
TGF-beta increases EGF receptor levels in NRK cells [17] and the 
combination ofTGF-beta, EGF, and PDGF was shown to evoke the 
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greatest response in cu ltured dermal fibroblasts [18]. Therefore, the 
effects on epidermal outgrowth ofTGF-beta were measured in the 
presence ofEGF and PDGF. FBS was used in these experiments at a 
concentration of 1 %, which was sufficient for explant viability but 
low enough to permit measurement of modulation by added factors. 
MATERIALS AND METHODS 
Materials RPM! 1640 Medium, FBS, and antibiotic/antimycotic 
were obtained from GIBCO Laboratories (Grand Island, NY) . Tis-
sue cu lture dishes were purchased from Corning Glass Works 
(Corning, NY). NTB-2 emulsion was obtained from Eastman 
Kodak Company (Rochester, NY) . Chemicals and biochemicals 
were reagent grade. Human platelet-derived TGF-beta and mouse 
EGF were generously provided by Dr. Anita Roberts and Dr. Mi-
chael Sporn (National Cancer Institute) . HPLC-purified human 
PDGF was p~rchased from Collaborative Research, (Lexington, 
MA). Domestic wh ite SWl11e were supplted by Sullivan Farm (In-
dus~ry, PA). Al1l.mals had been raise? Ill .confined housing to protect 
their S~ll1 from ~ryury and were mall1tall1ed 111 the University Cen-
tral Anuual FaCilIty (approved by AAALAC) 2 weeks prior to use. 
They received water and a complete SWll1e grower diet ad libitum 
and were housed in pens controlled for temperature (20 -23° ) and 
light (12h/12h, li ght:dark). 
EXJ?lant Preparation For each experiment a skin specimen was 
eXCised from the paravertebral regIOn of a young swine (2 - 4 
~onths old) . The a111mal, wluch had received no previous anesthe-
sia or treatment, was anesthetized with ketamine (300 mg, i.m.) and 
halothane (2 - 4%, open mask) . The skin was excised with an e1ec-
trokerato~le at a d~pth of 0.2 - 0.3 mm and explants were prepared 
USl11g stenle techl1lque as previously described [19] . 
Explants were incubated in culture medium RPMI 1640 contain-
ing 1 % FBS, antibiotic/antimycotic (200 units/ml penicillin 
200 pg/n~1 streptomycin and 500 n.g/I~l fun~izone) and one or ~ 
comblllatlOn of growth factors as Illdlcated 111 each experiment. 
TGF-beta was added in concentrations varying between 0.01 and 
10 ng/ml, EGF was added at a concentration of 5 ng/ ml , and 
PDGF was tested at a concentration of 2.5 units/ml. (One unit/ ml 
~DGF produces half maximal incorporation of tritiated thymidine 
mto Balb C/3T3 cells .) Medium with 1 % FBS was the control for 
all experiments. A few explants (l ess than 5%) did not adhere to the 
culture dish es and were not included in the evaluation. 
Initiat ioll oj OUlgrolllth: The explants were examined daily under a 
phase contrast microscope for initiation of epidermal outgrowth. 
The number of growing explants was determined for each treat-
ment group and is expressed as a percentage of the total explants for 
each group, excluding nonadherent samples. Comparisons between 
treatment groups were evaluated using the chi-square test. 
Epiderm(/ I Outgrowth: When growth was detected, the size of the 
epidermal sheet (radius of outgrowth) was measured daily at the 
same time each day by semi-automated image analysis (Bioquant, R 
& M Biometrics Corporation, N ashville, Tennessee) in conjunction 
with a phase-contrast microscope as previously described by Hebda 
et al [19]. The data were subjected to analysis of variance with 
repeated measures. The two-tailed least significant difference test 
was used to compare individual differences between treatment 
groups on each day of outgrowth. For autoradiography experi-
ments, the area of the epidermal sheet was measured after fixation 
and stainin g. 
Autora~iography: Explants were grown on sterilized microscope 
sltdes 111 th e presence of serum and growth factors as described 
above. On Days 1,2, and 3 [3H]thymidine (2 uCi/ml) was added to 
selected cu lture dishes in each treatment group and incubated for 
24. h. Then the slides were fixed and processed for autoradiography 
uSll1g Kodak NTB-2 emu lsion [20] . After incubation at 4°C for 2 
weeks the slides were developed and stained with Papanicolaou 
stain [21] . T he specimens were measured for number of labeled 
nuclei per mm2 . 
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RESULTS 
Throughout the 7 d of eva luation, explant cultures were found to 
have the morphology and growth characteristics ofkeratinocytes as 
described by Flaxman [22] and others [23 ,24]. The cells grew as an 
Intact sheet with "stretched" epidermal cells at the leading edge and 
typical cuboida l cells within the intact sheet. As cultures grew and 
matured, the sheets became multilayered with squames, and stained 
positive for keratin [21]. Fibroblasts were absent in early cultures 
and absent or negligible in later cultures . 
Initiation of Outgrowth Without additional growth supple-
ments, explants in 1 % FBS required up to 3 d in culture to initiate 
outgrowth (See Fig la, pallel A) . By Day 3, 70% of the samples had 
migrating epidermal sheets . With the addition ofTGF-beta, there 
was a marked increase in the number of explants growing on Days 1 
and 2 as shown in Fig la (pallels B-E). This increase was observed 
with concentrations ofTGF-beta as low as 0.01 ng/ml , and reached 
a plateau at 1 ng/ ml TGF-beta. At 10 ng/ml TGF-beta, the stimu-
latory effect was diminished. By the third day of culture, the final 
percentage of growing explants was the same in the untreated con-
trol (70%) and the TGF-beta groups (65 -80%), showing no net 
increase. 
In the same experiments, the combined effects ofEGF (5 ng/m1) 
and TGF-beta were evaluated (Fig Ib). In Fig Ib, the first group on 
the left (pallel A) shows the effect ofEGF alone. Compared with the 
control group in Fig 1a (pallel A), EGF had no effect on Day 1, but 
produced an increase in the number of growers on Day 2, and by 
Day 3, 90% of the explants were growing with EGF compared with 
70% for the con trol. The resu lts with TGF-beta plus EGF were 
comparable to the corresponding results with TGF-beta alone (Fig 
la) , showing an increase in the percentage of growing explants on 
Day 1. But in the presence of 5 ng/ ml EGF, this increase was con-
centration-dependent for TGF-beta, suggesting a possible synergis-
tic effect. This effect was most clearly demonstrated with 10 ng/ml 
TGF-beta [Fig Ib, pallel E (compare with Fig la, pallel E)]. The 
number of explants growing on Day 3 was not altered by the addi-
tion of TGF-beta [Fig Ib , (compare pallels B-E with patlei A )J, 
which is consistent with the results in Fig la . 
The early initiation of outgrowth with TGF-beta is also evident 
in the photomicrographs of representative cultures on Day 2, 
shown in Fig 2. The morphology of fl attened cells in a monolayer is 
characteristic of migratory keratinocytes . 
These results show that 1) TGF-beta consistently produced an 
earlier initiation of outgrowth, but did not change the number of 
samples that ultimately grew; 2) EGF in medium with 1% FBS 
increased the percentage of growing explants to approximately 90% 
on Day 3; and 3) EGF alone did not produce early initiation, but 
5 ng/ml EGF added with TGF-beta at 10 ng/ml produced earlier 
initiation of outgrowth. The effect ofTGF-beta on early initiation 
of outgrowth required the presence of serum (> 0.1 %). Bovine pitu-
itary extract [25] could not substitute for serum in these experiments 
because explants did not initiate outgrowth in serum-free medium 
containing bovine pituitary extract, without or with TGF-beta (data 
not shown). 
F.pidermalOutgrowth The early stage of explant cultures is the 
" migratory phase" (Days 1- 3) during which there is no measurable 
cell division, and the later stage is the "mitotic phase" (Days 4 - 7) in 
which there is a large increase in the mitotic index [23] . To deter-
mine the effects ofTGF-beta and EGF on each phase of outgrowth, 
viable (growin g) cultures were measured daily for 4 d, then on Day 
7. The resu lts are shown in Fig 3. In Fig 3(/ the data show that 
1 ng/ml TGF-beta increased the rate of outgrowth during the "mi-
gratory phase" (Days 1-3), but had no additional effect on the 
" mitotic phase" as reflected by the outgrowth from Days 4 - 7. A 
concentration of 1.0 ng/ml of TGF-beta was optimal; higher and 
lower concentrations of TGF-beta (10, 0.1 and 0.01 ng/ml) pro-
duced outgrowth that was not significantly different from the con-
trol (data not shown) . 
In Fig 3b the data show that in the presence of EGF, explant 
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Figure L a: Initiation of Outgrowth with Transforming Growth Factor-
beta. The graph shows percent growing explants with 1% FBS Control 
(pallet A) and 1 % FBS plus various concentrations ofTGF-beta (panels B- E). 
The bars indicate the percentage of growing expbnts On Days 1,2, and 3 of 
culture. The asterisk indicates the values that arc different from the concrol 
(pallet A) for each day, p < 0.05. b: Initiation of Outgrowth with Trans-
fonning Growth Factor-beta and Epidermal Growth Factor. This graph 
shows percent growing explants with 1 % FBS plus 5 ng(ml EGF (pallel A) 
and 1% FBS plus 5 ng(ml EGF plus various concentrations ofTGF-heta 
(pa/lels B - E). This series of treatments was evaluated in the same experi-
ments as the seri es described in Fig 1a so that the resu lts can be compared 
directly. The bars indicate the percentage of growing cxplants on Days 1,2, 
and 3 of culture. The pillS sigH indicates the va lues that are different from 1 % 
FBS alone (Fig la, panel A), and the asterisk indicates the values that arc 
different from FBS plus EGF (Fig H, panel A), p < 0.05. 
cultures grew at the same rate as the controls during the "migratory 
phase," but had an increased rate of outgrowth during the "mitotic 
phase." The combination of TGF-beta and EGF produced greater 
outgrowth during the "migratory phase" (Days 1- 3) compared 
with EGF alone, but there was no additional effect dueing the "mi-
totic phase" (Days 4 -7) compared with EGF alone. The stimula-
tory effect on th e "migratory phase" was maximal with 10 ng/ml 
TGF-beta (Fig 3b), but was also obtained with 1.0 ngjml TGF-beta 
(data /lot shown). 
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Combined Effects ofTGF-beta, EGF, and PDGF on Epidel: • 
mal Outgrowth Epidermal outgrowth was measured With 
PDGF alone and with PDGF plus 5 ng/ml EGF and 1 ng/ml TGF. 
beta. The results are shown in Table 1. PDGF-treated groups did nOt 
grow better than the control s with respect to either percent growing 
expJants or radius of outgrowth, and in fact there were fewer 
growers and less outgrowth on Day 1 in the presence of PDGF_ 
Autoradiography Incorporation of[3H1thymidine into keratino. 
cytes was used to estimate the mitotic index of the growi ng epider. 
mal sheets to see whether TGF-beta was producing early initiatioll 
of outgrowth by stimulating mitosis. The results shown in Table It 
indicate that this was not the case. On Day 1, only cultures ill 
medium with TGF-beta showed outgrowth, but none of the cells ill. 
the epidermal sheet were labeled. T herefore, outgrowth was due to 
migration rather than to mitosis. On Day 2 there was outgrowth it, 
all of th e groups, but the explants grown with TGF-beta did not 
differ from the control in [3H)thymidine incorporation. Only the 
5% FBS group showed increased labelin g_ Results for Day 3 were 
similar. The combination ofTGF-beta and EGF had no additional 
effect on incorporation of labeL 
DISCUSSION 
The epidermal explant culture system was used because the author 
and others have found it to be a good in vitro model for epitheliali. 
zation [1 9,22 - 24,26 - 29]. The tissue structure of the epidermis and 
dermis is partly retained, and, although systemic responses are ab. 
sent, localized interactions including dermal-epidermal and base_ 
ment membrane-epidermal interactions remain undisrupted. OUt-
growth from explants begins with attachment, spreading, and 
migration of epidermal cells from the edges of the explant. As the 
epidermal sheet grows, cells begin to divide and then to stratify and 
differentiate [22]. Therefore, the exp lant cu lture system reflects the 
early wound environment and provides an in vitro model for epi-
dermal wound healing that cannot be achieved with pure epidermal 
cell cul tures. Explant cu ltures have been used to evaluate potential 
effectors of epidermal cells, including adenine nucleotides l26]. cat-
ccholamines [261, EGF (24). methotrexate (27), platelet homoge-
nate (19]' fibronectin [28]. and cyclosporin A [291. 
TGF-beta at 0.01 ng/ml produced ea rlier initiation of outgrowth 
and no further increase was observed at higher concentrations (Fig 
1 a). However, a maxim um rate of outgrowth during the "migratory 
phase" was obtained with TGF-beta at 1.0 ng/ml (Fig 3a} There-
fore, for sustained outgrowth it appears that 1.0 ng/ml TGF-beta is 
optimal. 
The stimulatory effect of EGF on the rate of ep idermal out-
growth, previously demonstrated by others [24), was also observed 
in these experiments. In addition, EGF produced a greater percent-
age of growing explants. The combination of TGF-beta and EGF 
resulted in early initiation of outgrowth (TGF-beta effect), in-
creased percent growi ng explants (EGF effect), and an increased rate 
of outgrowth (TGF-beta effect on Days 1 -3, EGF effect on Days 
4 - 7). The effects of TGF-beta and EGF together were primarily 
additive, although th e effect Oil initiation of outgrowth on Day 1 
shown in Fig 1 b (panel hj is suggestive of a possible sy nergistic 
activity. Under the conditions tested, TGF-beta did not affect the 
rate of mitosis during the "migratory phase" of cu lture as measured 
by (3HJthymidine incorporation. These studies show thatTGF-beta 
is all important factor for initiating and stimulating epidermal cell 
migration, wh ile continued outgrowth is stimulated by EGF, a 
knowl1mitogen for epidermal cells [301. The combination ofTGF-
beta and EGF produced the greatest percentage of growing explanrs 
and the earliest and fastest outgrowth. 
Others have reporred that TGF-beta inhibits proliferation (pro-
motes differentiation) of human keratinocytes as determined by 
incorporation of [3H1thymidine into cultures of rapidly dividing 
ce ll s (6] and clonal growth rate [71. The work presented here dem-
onstrates a stim ul atory effect ofTGF-beta on initiation of epidermal 
ce ll migration and on the rate of epidermal outgrowth during the 
"m'igratory phase" of explant cu lture, involving activities other 
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Figure 2. Epidermal Outgrowth on Day 2. Representative explants (100X) are shown cultured in control medium containing 1 % FBS (a) and medium 
supplemented with 1 ng/ml TGF-beta (b), "10 ng/ml TGF-beta (e), 5 ng/m l EGF (d), 1 ng/ml TGF-beta and 5 ng/ml EGF (e), and 10 ng/ml TGF-beta and 5 
ng/ml EGF (f). Figures are labeled to show the explant (E) and the epiderma l outgrowth (0). 
Table I. Combined Effects of TGF-beta, EGF, and PDGF on Epidermal O utgrowth 
% Growing Explants 
N =20 
Treatment Day 1 Day 2 Day 3 
Control 40 85 90 
PDGF 20' 89 89 
TGF-beta + EGF 79 79 89 
TGF-beta + EGF + POGF 60' 80 95 
a The va lues indicated were lower than the corresponding treatment without PDGF (I' < 0.05). 
b The values indicated were hi gher than th e co ntrol (I' < 0.05). 
Radius of Outgrowth 
(um ± SEM) 
Day 2 Day 4 
45 ± 13 262 ± 27 
3 ± 3' 274 ± 31 
82 ± 121, 340 ± 201, 
69 ± 16 317 ± 33 
Day 7 
425 ± 40 
483 ± 36 
733 ± 23b 
653 ± 46b 
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Figure 3. a: Epidermal Outgrowth with Transforming Growth Facto r-
beta. The Curves show epidermal ce ll outgrowth with 1 % FBS Control and 
with 1 % FBS plus 1.0 ngjml TGF-bcra. Outgrowth with TGF-bcra was 
greater than the control on Days 2, 3, 4, and 7, p < 0.05, as indicated by an 
asterisk; however, therc was no additio nal increasc in the rate of outgrowth 
(slope) after Day 3. b: Epidermal Outgrowth with Transforming Growth 
Factor-beta and Epidermal Growth Factor. Th c curves show cpidermal cell 
outgrowth with 1 % FBS Control , with 1 % FBS plus 5 ng/ml EGF , and with 
1 % FBS plus 10 ngjml T GF-beta and 5 ng/ml EGF. Outgrowth with EGF 
was greater than the control o n Days 4 and 7 as indicated by a plus siglt, 
p < 0.05 . Outgrowth with TGF-beta plus EGF was grea ter than EGF alone 
on every day of eva luation , as indicated by an asterisk, p < 0.05; however, 
there was no add itional increasc in the ra te of outgrowth (slope) on D ays 4 
and 7. 
than mitosis; namely, attachment, spreadin g, and motility. These 
observations suggest that TGF-beta may direct epidermal cells 
toward migration rather than division, as is needed during the early 
stages of epidermal wound healing. TGF-beta directs human bron-
chial epithelial cells to undergo terminal differentiation rather than 
proliferation [8]. Therefore, TGF-beta may be a key factol' for di-
recting epithelial cells along a pathway other than proliferation 
(i.e ., migration, differentiation). 
Although PDGF has a stimulatory effect on mesenchymal cells, it 
was not found to stimulate epidermal cell outgrowth fr0111 explants 
in these studies. Because the PDGF-receptor appears to be specific 
for mesenchymal cells, this findin g is not surprising. This study 
additionally demonstrates that PDGF had no indirect stimulatory 
effect on epidermal outgrowth via the dermal tissue in the explants, 
whether PDGF was added alone or with TGF-beta and EGF. Our 
laboratory reported previously [19] that a partially-purified com-
mercial preparation of PDGF had a sli ght stimulatory effect on 
epidermal outgrowth. In view of the results reported here, earlier 
THE JO URNAL O F INVESTIGATIVE DERMATOLOGy 
Table II. lncorporation of [3H]Thymidine into Keratinocytes o f 
the Growing Epidermal Sheets 
Labeled Nuclei/111m2 (±SEM)* 
Treatment Day 1 Day 2 Day 3 
Control NG' 7.4 ± 4.3 17.4 ± 4.8 
TGF-bcta 0" 4.1 ± 3.0 11.1 ±2.~ 
EGF N G 9. 3 ± 3.6 9.3 ± 1. ~ 
TGF-beta + EGF 0 3.1 ± 1.0 5.6 ± 2.0 
5% FBS N G 23 .4 ± 5.5 35.8 ± 6.9 
• N G: No Gro wers. 
b 0: Explants were growing but th ere were no labeled nuclei. 
observations may have been due to a slight amount ofTGF-beta Or 
another platelet-derived factor that co-purified with PDGF. 
Roberts and Sporn [4] have discussed the role of TGF-beta in 
other culture systems. TGF-beta was named for its ability to pro-
duce anchorage- independent growth of cells in soft agar culture. 
Now it has been shown that TGF-beta also promotes anchorage_ 
dependent outgrowth (the initiation of migration of keratinocytes 
in explant cultures). 
Takashima and Grinnell [28] reported that epidermal explants 
require 3- 4 d to express fibronectin receptor funct ion in vitro and 
that this receptor function is required for continued outgrowth. 
One interpretation of the TGF-beta effect is that by Day 1 of culture 
TGF-beta induces the expression of the fibronectin receptor or the 
receptor for another attachment factor on the keratinocyte surface 
and enables epidermal cel l migration to begin. 
It has been proposed that TG F-beta is a physiologically important 
wound hormone. It is stored in platelets and released at the site of 
injury . TGF-beta stimulates fibrosis when injected into wound 
chambers implanted in the backs of rats [14] and when injected into 
the nape of the neck of newborn mice [4,9] . This study enlarges the 
role ofTGF-beta to include the epidermis. By accelerating the start 
of epithelialization, it may be an important initiating signal for 
epidermal wound hea ling. Together with other cytokines, TGF-
beta may be orchestrating the events that occur during the"healing 
process. 
NOle added in proof It was recently reported that a 12-h incubation 
with TGF-beta evoked an increase in subunit precursors for cell 
adhesion receptors in two epithelial cell lines [31] . 
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CONFERENCE ON STRUCTURE, MOLECULAR BIOLOGY AND 
PATHOLOGY OF COLLAGEN 
This con fe rence will be held at the H yatt Regency, B ethesda, MD , o n April 3- 5 , 1989. D uring 
the pas t fiv e yea rs t here has been an expl osion of knowled ge in the area of extracellular m atrix 
bio logy. This confere nce will all ow interaction between bio logists, biochemists, and physicians 
interested in one o f th e m;uor compo nents in extracellular m atrices-coll agen . Subjects to be 
covered in this conference include a) collagen structure; b) structure and regulatio n of collagen 
genes; c) collagen biosy nthesis and supram olecular assembly; d) developmcntal bio logy of 
collagen; e) extracellular m atrix and neurobio logy; and f) genetic and acquired dise:lses of 
collagcn . 
T here will be contributed poster sessions in conjunctio n with this conference. T he deadline fo r 
submissio n o f abstracts is Decelllber 1, 1988. A 200-w ord summary of w o rk to be p resen ted 
sho uld be sent to: D r. Raul F leischmaj er , D ept. of Dermato logy, Mt. Sinai School of M edicine, 
N ew Y o rk, NY 10029. (Abstract fo rm is no t necessary.) 
